Biohaven与SK生物制药近日宣布，双方已正式签署一项具有里程碑意义的全球战略许可协议。此次合作聚焦于新型Kv7离子通道平台，以及该平台下针对癫痫治疗的领先候选药物Opakalim。
根据协议条款，Biohaven将获得Opakalim及Kv7离子通道平台在全球范围内的独家开发和商业化权利。这一举措标志着两家公司在神经系统疾病治疗领域迈出了关键一步。
Kv7离子通道在调节神经元兴奋性方面扮演着至关重要的角色，而Opakalim作为一种靶向该通道的新型药物，有望为癫痫患者提供一种全新的治疗选择。Biohaven在神经科学领域的深厚积淀与SK生物制药的创新研发能力相结合，无疑将加速这一潜力巨大的药物管线的临床推进。
业内分析人士指出，此次合作不仅彰显了Biohaven致力于为难治性神经系统疾病患者带来突破性疗法的决心，也反映了SK生物制药对其平台技术价值的充分认可。随着全球癫痫治疗需求的不断增长，这一战略联盟的建立，或将重塑未来癫痫治疗的格局。双方预计将在接下来的数月内启动相关监管申报工作，并着手规划后续的临床试验路径。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.